Results 29 patients were seen by cardiology in the outpatient setting, all had a diagnosis of schizophrenia. Mean age 43 ±12 years; 34% female (n=10; table 1). 59 others underwent diagnostic testing but were never referred for review.
that it is not used as commonly as its effectiveness dictates it should be. We studied referrals to our Cardiology Unit from our linked national psychiatric unit to characterise the cardiac status in these individuals and determine outcome. Methods Retrospective review of all adult patients on clozapine referred to our cardiology unit over 9 years. Electrocardiograms and echocardiographic data was collected as was mortality data. Students t-test, Mann-Whitney U and linear regression were used to analyse results. Results 29 patients were seen by cardiology in the outpatient setting, all had a diagnosis of schizophrenia. Mean age 43 ±12 years; 34% female (n=10; table 1). 59 others underwent diagnostic testing but were never referred for review.
Median left ventricular ejection fraction (LVEF) was 52 (IQR44%-55%), median HR 98 (IQR85-114bpm). No significant difference in age at review and LVEF, QRS duration, heart rate or QTc interval. There was no significant relationship between duration on clozapine and LVEF (p=0.77) at review. There was a significant difference in length of time on clozapine and QTc interval (p=0.02; r=0.46; figure 1 ).
Follow-up time was 4.4 years(IQR 2-6) from initial review; 3 patients died (subarachnoid haemorrhage, aortic aneurysm rupture, suicide). 14 of the surviving 26 (54%) remain on clozapine at most recent follow-up and demonstrated no significant change in the LVEF during this time (p=0.66).
Those with LV impairment tended to be seen earlier than those who developed tachycardia without LV impairment (4.7 vs 7.2 years; p=0.27). Patients in the former group were far more likely to have clozapine discontinued compared to those in the tachycardia group (p=0.03). Discussion Clozapine use is associated with persistent tachycardia, myocarditis and cardiomyopathy; the latter carry significant morbidity and mortality. Despite being very effective, many will have clozapine stopped if there is evidence of cardiac toxicity. Our experience suggests that the shortmedium term outcome in these patients is acceptable with very low cardiac risk and no observable deterioration in LVEF.
Our findings support two distinct modes of cardiac toxicity. The underlying pathophysiology is not yet well defined and is likely to include patient-specific factors. Our data supports the feeling that tachycardia represents a benign process as all our patients had normal LVEF at the time of review.
Prospective studies are required in this complex group; the significance of QTc prolongation with clozapine use remains unclear and further study is warranted. We suggest that these patients should be managed in an interdisciplinary manner with close liaison between cardiologists and psychiatrists.
Introduction There have been many cases observed in our cardiology wards and non-cardiology wards where heart failure patients are not having optimum fluid management and uptitrating therapy. One case led a patient to have prolonged hospital stay and outcome was death. Therefore, this project is important to raise awareness.
Currently, we only have a basic daily weight chart, which the nurses record the patients weight every morning. The heart failure medications are separately found on the drug chart, and bloods are found on Cyberlab. Plus the heart failure guidelines are found on the European Society of Cardiology website. This shows that it takes a lot of effort and can cause time-consuming problems when accumulating this information together for heart failure monitoring; especially during busy ward round. For effective heart failure monitoring, a new proforma was devised, which consists of daily weight, medications, U and Es with electrolytes, patient heart failure details and admission weight. The guidelines (flow chart) are found at the back. This will be filled in by both nurses and doctors. This effectively improves titrating heart failure medications for better weight loss secondary to fluid overload.
Introduction Heart transplantation and mechanical circulatory support (MCS) improve survival in selected patients with advanced heart failure and an adverse prognosis. Soluble ST2 is a protein belonging to the interleukin-1 receptor family. ST2 is released in response to cardiomyocyte stess and thought to be a marker of adverse prognosis. We examined the association between ST2 levels and currently accepted markers of adverse prognosis in patients with advanced heart failure. Methods We included 20 consecutive outpatients who were assessed for heart transplantation at Papworth Hospital over ten weeks. All patients underwent echocardiography, six minute walk testing, cardiopulmonary exercise testing and right heart catheterisation, in addition to blood tests including serum ST2 measurement using a commercial assay. Prognosis was estimated using the Seattle Heart Failure Model (SHFM) and the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) scores. A multi-disciplinary team decided whether listing for heart transplantation was indicated. We examined the association between ST2 levels and other markers of adverse prognosis. Results Ten patients were too well to be listed for heart transplantation (group A) and ten patients were sufficiently unwell to be listed for heart transplantation (group B). There was no difference in age, gender or body mass index. Key prognostic variables are presented in table 1. Compared with patients in group A, patients in group B had higher ST2 levels, lower peak VO 2 , shorter six minute walk distance and higher SHFM Abstract 14 Table 1 
